Summary
The present study investigated the interaction between c-erbB2 overexpression and the response to first-line endocrine therapy in patients with advanced breast cancer. The primary tumours of 241 patients who were treated at first relapse with endocrine therapy were assessed for overexpression of c-erbB2 by immunohistochemistry. c-erbB2 was overexpressed in 76 (32%) of primary breast cancers and did not correlate with any other prognostic factor. The overall response to treatment and time to progression were significantly lower in patients with c-erbB2-positive tumours compared to those that were c-erbB2-negative (38% vs 56%, P = 0.02; and 4.1 months vs 8.7 months, P < 0.001, respectively). In multivariate analysis, c-erbB2 status was the most significant predictive factor for a short time to progression (P = 0.0009). In patients with ER-positive primary tumours treated at relapse with tamoxifen (n = 170), overexpression of c-erbB2 was associated with a significantly shorter time to progression (5.5 months vs 11.2 months, P < 0.001). In conclusion, overexpression of c-erbB2 in the primary tumour is an independent marker of relative resistance to first-line endocrine therapy in patients with advanced breast cancer. In patients with ER-positive primary tumours, the overexpression of c-erbB2 defines a subgroup less likely to respond to endocrine therapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Allred, D. C., Clark, G., Tandon, A., Schnitt, S. J., Gilchrist, K. W., Osborne, C. K., Tormey, D. C. & McGuire, W. L. (1992). HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599–605.
Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hinna, W., Lickley, L., Wilkinson, R., Qizlbash, A., Ambus, U., Lipa, M., Weizel, H., Katz, A., Baida, M., Mariz, S., Stoik, G., Dacamara, P., Strongitharm, D., Geddie, W. & McCready, D. (1998). neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16: 1340–1349.
Archer, S. G., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I. & Robertson, J. F. (1995). Expression of ras p21, p53 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266.
Barnes, D. M., Lammie, G. A., Millis, R. R., Gullick, W. J., Allen, D. S. & Altman, D. G. (1988). An immunohistochemical evaluation of c-erbB2 expression in human breast carcinoma. Br J Cancer 58: 448–452.
Barnes, D. M., Millis, R. R., Beex, LVAM, Thorpe, S. M. & Leake, R. E. (1998). Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 34: 1677–1682.
Baselga, J., Tripathy, D., Mendelsohn, J., Baugham, S., Benz, C. C., Dantis, L., Sklarin, N. J., Seidman, A. D., Hndis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C. & Norton, L. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737–744.
Benz, C. C., Scott, G. K. & Sarup, J. C. (1992). Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85–95.
Berns, EMJJ, Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, HYWCM, Portengen, H. & Klijn, J. G. M. (1995). Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159: 11–18.
Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., Ryden, S. & Sigurdsson, H. (1994). ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137–144.
Carlomagno, C., Perrone, F., Gallo, C., De Laurentis, M. D., Lauria, R., Morabito, A., Pettinato, G., Panico L D’Antonio, A., Bianco, R. & De Placido, S. (1996). c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702–2708.
Charpin, C., Garcia, S., Bouvier, C., Martini, F., Lavaut, M-N, Allasia, C., Bonnier, P. & Andrac, L. (1997). c-erbB2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients’ overall and disease-free survival. Br J Cancer 75: 1667–1673.
Ciocca, D. R., Fujimura, F. K., Tandon, A. K., Clark, G. M., Mark, C., Lee-Chen, G. J., Pounds, G. W., Vendely, P., Owens, M. A., Pandian, M. R. & McGuire, W. L. (1992). Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst 84: 1279–1282.
Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer. (1996). J Clin Oncol 14: 2843–2877.
Coussens, L., Yang-Feng, T. L., Liao, T. L., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., Levinson, A. & Ullrich, A. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139.
Elledge, R. M., Green, S., Ciocca, D., Pugh, R., Allred, C. A., Clark, G. M., Hill, J., Ravdin, P., O’Sullivan, J., Martino, S. & Osborne, C. K. (1998). HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 4: 7–12.
Elston, C. W. (1984). The assessment of histological differentiation in breast cancer. Aust NZ J Surg 54: 11–15.
Gullick, W. J., Love, S. B., Wright, C., Barnes, D. M., Gusterson, B., Harris, A. L. & Altman, D. G. (1991). c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438.
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C-M, Goloum, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Burki, K., Castiglione, M., Collins, J., Lintner, J. & Senn, H-J (1992). Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10: 1049–1056.
Hayward, J. L., Carbone, P. P., Heuson, J. C., Kumaoka, S., Segaloff, A. & Rubens, R. D. (1977). Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289–1294.
Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E. & Yarden, Y. (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15: 254–264.
Kath, R., Hoffken, K. & Otte, C. (1993). The neu oncogene product in serum and tissue of patients with breast carcinoma. Ann Oncol 4: 585–590.
Kern, F. G., Cheville, A. L. & Liu, Y. (1990). Growth factor receptors and the progression of breast cancer. Semin Cancer Biol 1: 317–328.
King, R. J. B., Redgraves, J. & Hayward, J. L. (1979). The measurement of receptors for oestradiol and proesterone in human breast tumours. In Steroid Receptor Assays in Breast Tumours: Methodological and Clinical Aspects, King RJB (ed), pp. 55–73, Alpha-Omega: Cardiff
Klijn, J. G. M., Berns, EMJJ, Bontebal, M. & Foekens, J. (1993). Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19SB: 45–63.
Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K. & Isola, J. (1996). Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14: 2584–2589.
Leitzel, K., Teramoto, Y., Sampson, E., Mauceri, J., Langton, B. C., Demers, L., Podczaski, E., Harvey, H., Shambaugh, S., Volas, G., Weaver, S. & Lipton, A. (1992). Elevated soluble c-erbB2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10: 1436–1443.
Leitzel, K., Teramoto, Y., Konrad, K., Chinchilli, V. M., Volas, G., Grossberg, H., Harvey, H., Demers, L. & Lipton, A. (1995). Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129–1135.
Manni, T. & Trujillo, J. E. Marshall (1989). Anti-hormone treatment of stage IV breast cancer. Cancer 43: 444–450.
Newby, J. C., Johnston, S. R. D., Smith, I. E. & Dowsett, M. (1997). Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643–1651.
Niehans, G. A., Singleton, T. P. & Dykoski, D. (1993). Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 5: 1230–1235.
O’Malley, F. P., Saad, Z., Kerkvliet, N., Doig, G., Stitt, L., Ainsworth, P., Hundal, H., Chambers, A. F., Turnbull, D. I. & Bramwell, V. (1996). The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB2 in lymph node negative breast cancer. Hum Pathol 27: 955–963.
Pietras, R. J., Arboleda, J. & Reese, D. M. (1995). HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435–2446.
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W., Sliwkowski, M., Akita, R., Brandeis, J., Paterson, M. C. & Slamon, D. J. (1993). Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53: 4960–4970.
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J-Y, Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Philips, R. N., Ross, J. S., Wolman, S. R. & Flom, K. J. (1997). HER-2/neu gene amplification characterised by fluoresence in situ hybridisation: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894–2904.
Ravdin, P. M., Green, S., Door, T. M., McGuire, W. L., Fabian, C., Pugh, R. P., Carter, R. D., Rivkin, S. E., Borst, J. R., Belt, R. J., Metch, B. & Osborne, C. K. (1992). Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective SWOG study. J Clin Oncol 10: 1284–1291.
Rubens, R. D. & Hayward, J. L. (1980). Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer 46: 2922–2924.
Saceda, M., Grunt, T. W., Colomer, R., Lippman, M. E., Lupu, R. & Martin, M. B. (1996). Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology 137: 4322–4330.
Sjogren, S., Inganas, M., Lindgren, A., Holmberg, L. & Bergh, J. (1998). Prognostic and predictive value of c-erbB2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16: 462–469.
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. & Press, M. F. (1989). Studies of the HER-2/neu proto-oncogene in human breast cancer and ovarian cancer. Science 244: 707–712.
Stal, O., Ferno, M., Borg, A. & Nordenskjold, B. (1997). ERBB2 expression and benefit from 5 versus 2 years of adjuvant tamoxifen for postmenopausal stage II breast cancer patients. Breast Cancer Res Treat 46: 32 (abstr)
Tetu, B. & Brisson, J. (1994). Prognostic significance of the pattern of immunostaining and adjuvant therapy. Cancer 73: 2358–2365.
Witters, L. M., Kumar, R., Chinchilli, V. M. & Lipton, A. (1997). Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1–5.
Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R. C., Farndon, J., Cairns, J., Harris, A. L. & Horne, C. (1992). Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121.
Yamauchi, H., O’Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hosch, S. & Hayes, D. F. (1997). Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518–2525.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Houston, S., Plunkett, T., Barnes, D. et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79, 1220–1226 (1999). https://doi.org/10.1038/sj.bjc.6690196
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690196
Keywords
This article is cited by
-
Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
Drugs - Real World Outcomes (2024)
-
Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery
Molecular Imaging and Biology (2023)
-
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
npj Breast Cancer (2022)
-
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
Oncogene (2017)
-
Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar
Comparative Clinical Pathology (2016)
